DiaMedica Therapeutics Advances DM199 for Innovative Ischemic Disease Treatments and Upcoming Financial Insights

### DiaMedica Therapeutics Advances in Ischemic Disease Treatments

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, announces its commitment to developing innovative therapies for severe ischemic diseases, with a particular focus on acute ischemic stroke and preeclampsia. The company’s lead candidate, DM199, marks a significant advancement in treatment options by being the first synthetic form of the KLK1 protein. This protein has already established its efficacy in Asian markets for managing conditions related to ischemic diseases and vascular health. By leveraging this established treatment, DiaMedica aims to address critical gaps in the current therapeutic landscape, offering new hope for patients suffering from these severe conditions.

As DiaMedica prepares to release its third quarter 2024 financial results on November 13, the company also gears up for a live conference call on November 14, 2024. This call is anticipated to provide valuable insights into the company's ongoing projects, strategic direction, and financial health. Attendees of the conference call can expect a comprehensive update on the company's advancements in clinical trials and the potential impact of DM199 on patient outcomes. This proactive approach to transparency not only informs stakeholders but also reinforces DiaMedica’s position within the biopharmaceutical industry as a leader in innovative treatment solutions.

The focus on severe ischemic diseases positions DiaMedica Therapeutics to capitalize on a significant unmet medical need. Ischemic stroke, for example, remains a leading cause of disability and death worldwide, creating a pressing requirement for effective treatments. The promising data surrounding DM199 suggests that it could significantly improve recovery rates and management of symptoms for patients affected by these conditions. As DiaMedica advances its clinical trials and prepares for potential market entry, the company continues to solidify its role as a key player in the development of advanced therapies for ischemic diseases.

In addition to its clinical initiatives, DiaMedica emphasizes the importance of stakeholder engagement through its upcoming conference call. By allowing investors and interested parties to gain firsthand knowledge of its operational updates, the company fosters a sense of community and transparency. Furthermore, the accessibility of the live webcast and subsequent playback options highlights DiaMedica’s commitment to keeping its audience informed over the long term.

As DiaMedica Therapeutics continues to navigate the complexities of biopharmaceutical development, its focus on ischemic diseases and innovative treatment technologies positions it for future success in an evolving healthcare landscape.